GSK launches $2.5 billion buyback, lifts sales target
Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains. The post ...
While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual results, but raised its ...
The increase comes as investors continue to hedge against geopolitical risks, particularly on fears over the impact of a ...
Stock prices in London were mixed on Wednesday afternoon, with a share price rise for GSK supporting the FTSE 100, though tariff worries continue to hang over equities. The FTSE 100 index rose 12.01 ...
GSK (LON: GSK) has issued an update which inevitably reflects the difficulties faced in the last year, while also providing a host of reasons to be more upbeat on future prospects. Concerns over the ...
If the GSK (LSE: GSK) share price was a video game, it would be flashing GAME OVER to me right now. Shares in the pharmaceutical giant started 2025 trading at a 12-month low. Although they picked ...
In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback